These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12544124)

  • 1. Comparison of I-123 and I-131 for whole-body imaging after stimulation by recombinant human thyrotropin: a preliminary report.
    Anderson GS; Fish S; Nakhoda K; Zhuang H; Alavi A; Mandel SJ
    Clin Nucl Med; 2003 Feb; 28(2):93-6. PubMed ID: 12544124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone.
    David A; Blotta A; Bondanelli M; Rossi R; Roti E; Braverman LE; Busutti L; degli Uberti EC
    J Nucl Med; 2001 Oct; 42(10):1470-5. PubMed ID: 11585859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
    Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
    Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma.
    Pacini F; Molinaro E; Lippi F; Castagna MG; Agate L; Ceccarelli C; Taddei D; Elisei R; Capezzone M; Pinchera A
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5686-90. PubMed ID: 11739420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin.
    Haugen BR; Ridgway EC; McLaughlin BA; McDermott MT
    Thyroid; 2002 Jan; 12(1):37-43. PubMed ID: 11838729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
    Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
    Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma.
    Pacini F; Molinaro E; Castagna MG; Agate L; Elisei R; Ceccarelli C; Lippi F; Taddei D; Grasso L; Pinchera A
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3668-73. PubMed ID: 12915653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma.
    David A; Blotta A; Rossi R; Zatelli MC; Bondanelli M; Roti E; Braverman LE; Busutti L; degli Uberti EC
    Thyroid; 2005 Feb; 15(2):158-64. PubMed ID: 15753676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human thyroid-stimulating hormone (Thyrogen) in thyroid cancer follow up: experience at a single institution.
    Wong R; Topliss DJ; Bach LA; Hamblin PS; Kalff V; Long F; Stockigt JR
    Intern Med J; 2009 Mar; 39(3):156-63. PubMed ID: 19383064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer.
    Torlontano M; Crocetti U; D'Aloiso L; Bonfitto N; Di Giorgio A; Modoni S; Valle G; Frusciante V; Bisceglia M; Filetti S; Schlumberger M; Trischitta V
    Eur J Endocrinol; 2003 Jan; 148(1):19-24. PubMed ID: 12534353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compliance with follow-up and the informative value of diagnostic whole-body scan in patients with differentiated thyroid carcinoma given recombinant human TSH.
    Cohen O; Dabhi S; Karasik A; Zila Zwas S
    Eur J Endocrinol; 2004 Mar; 150(3):285-90. PubMed ID: 15012612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma.
    David A; Blotta A; Rossi R; Zatelli MC; Bondanelli M; Roti E; Braverman LE; Busutti L; degli Uberti EC
    Thyroid; 2005 Mar; 15(3):267-73. PubMed ID: 15785246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
    Mazzaferri EL; Kloos RT
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.
    Haugen BR; Pacini F; Reiners C; Schlumberger M; Ladenson PW; Sherman SI; Cooper DS; Graham KE; Braverman LE; Skarulis MC; Davies TF; DeGroot LJ; Mazzaferri EL; Daniels GH; Ross DS; Luster M; Samuels MH; Becker DV; Maxon HR; Cavalieri RR; Spencer CA; McEllin K; Weintraub BD; Ridgway EC
    J Clin Endocrinol Metab; 1999 Nov; 84(11):3877-85. PubMed ID: 10566623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular technology and the recombinant TSH have changed diagnostics of thyroid carcinoma with positive I-131 whole body scan but low serum thyroglobulin.
    Montella L; Caraglia M; Abbruzzese A; Soricelli A; Prete SD; Squame G; Salvatore M
    Exp Mol Med; 2004 Jun; 36(3):268-73. PubMed ID: 15272239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of recombinant human thyrotropin-stimulated ¹²³I whole-body scintigraphy in the follow-up of patients with differentiated thyroid cancer.
    Alzahrani AS; AlShaikh O; Tuli M; Al-Sugair A; Alamawi R; Al-Rasheed MM
    Clin Nucl Med; 2012 Mar; 37(3):229-34. PubMed ID: 22310247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity of preparation with rhTSH or thyroid hormone withdrawal using ¹³¹I-whole body scans to identify metastases of differentiated thyroid cancer.
    Liepe K
    Int J Surg; 2015 Apr; 16(Pt A):107-112. PubMed ID: 25771100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human thyrotropin is helpful in the follow-up and 131I therapy of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine.
    Kohlfuerst S; Igerc I; Lind P
    Thyroid; 2005 Apr; 15(4):371-6. PubMed ID: 15876162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.